论文部分内容阅读
目的:回顾性分析我科胃癌术后复发与主要临床病理特征的关系,重点探讨术后复发时间及其相关因素。方法:在286例胃癌术后病人中,分析有完整随访信息的59例复发患者的临床数据,研究复发时间及其与临床分期和和辅助化疗的关系。结果:76.3%(45/59)的病人在术后1年内复发,中位复发时间为7个月(1-60个月),57.6%(34/59)为局部-区域复发。Ⅰ-Ⅳ期病人之间复发时间的差异无统计学意义(P>0.05,Kruskal-Wallis检验)。不同的辅助化疗周期数之间的复发时间的差异有显著性(P<0.05,Kruskal-Wallis检验)。结论:胃癌病人术后2年内是监测随访重点,辅助化疗有助于延长无复发生存。
Objective: To retrospectively analyze the relationship between postoperative recurrence and major clinical and pathological features of gastric cancer in our department, and to explore the time of postoperative recurrence and its related factors. Methods: Of 286 postoperative patients with gastric cancer, the clinical data of 59 patients with complete follow-up information were analyzed to investigate the relapse time and its relationship with clinical stage and adjuvant chemotherapy. Results: 76.3% (45/59) patients relapsed within 1 year after operation. The median time to recurrence was 7 months (1-60 months) and 57.6% (34/59) were local-regional recurrence. There was no significant difference in the relapse time between stage Ⅰ-Ⅳ patients (P> 0.05, Kruskal-Wallis test). There was a significant difference in the timing of recurrence between different adjuvant chemotherapy cycles (P <0.05, Kruskal-Wallis test). Conclusion: Gastric cancer patients are the focus of monitoring follow-up within 2 years after operation. Adjuvant chemotherapy can help prolong the recurrence-free survival.